Alternative therapies are needed for treating individuals with DME who’ve persistent macular edema and vision loss despite frequent anti-VEGF injections and in addition for sufferers who don't want or don't tolerate intravitreal injections, stated Jeffrey Heier, MD, Ophthalmic Consultants of Boston. Based on a compelling scientific background of preclinical and early medical data, AKB-9778 might provide a patient self-administered alternative that may be helpful in the treating diabetic macular edema. The randomized, double-masked, double dummy, Phase 2 research is designed to assess the protection and efficacy of AKB-9778 administered over three months as monotherapy and as an adjunct with ranibizumab in topics with DME.I am hoping that clinicians discover this volume useful in the administration of their patients, Biller wrote.
Affymax receives arbitration panel decision related to dispute against JNJ subsidiaries Affymax, Inc. today announced that it has received a decision from the arbitration panel reviewing its dispute against specific subsidiaries of Johnson and Johnson . The panel has decided that Affymax and JNJ are co-owners of particular intellectual property, including U.S. Patent quantities 5,773,569, 5,830,851, 5,986,047, among others linked to erythropoietin receptor agonists. In addition, the ruling motivated that JNJ is single owner of JNJ’s U.S.